EPAS1 and neoplasm: More perceivably, 78% (n = 28/38) of patients having larger tumour (larger than 40 mm in diameter) showed amplified EPAS1 DNA when compared to those of 54% (n = 24/44) of the patient bearing smaller tumour (40 mm or smaller in diameter) (Table 1).